Targeting the Bromodomain-containing protein 4 in ovarian clear cell carcinoma
Ovarian clear cell carcinoma (OCCC) is the second most common histopathological subtype of ovarian carcinoma (OC), making up 5-25% of all OC. Current treatment utilizing combination chemotherapy with cisplatin and paclitaxel have low efficacy with a 5-year survival rate of only 12%. Bromodomain-cont...
Saved in:
Main Author: | Wong, Erica Shiyi |
---|---|
Other Authors: | Vinay Tergaonkar |
Format: | Final Year Project |
Language: | English |
Published: |
2017
|
Subjects: | |
Online Access: | http://hdl.handle.net/10356/70625 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Nanyang Technological University |
Language: | English |
Similar Items
-
A Series of Ovarian Clear Cell and Endometrioid Carcinoma and their Association with Endometriosis
by: Chew, S., et al.
Published: (2013) -
Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling
by: Matsumura, N., et al.
Published: (2014) -
Gene regulation and tumor suppression by the bromodomain-containing protein BRD7
by: Mantovani, F., et al.
Published: (2014) -
Identification of serum cytokine clusters associated with outcomes in ovarian clear cell carcinoma
by: Yabuno, A., et al.
Published: (2021) -
Cysteine Deprivation Targets Ovarian Clear Cell Carcinoma Via Oxidative Stress and Iron-Sulfur Cluster Biogenesis Deficit
by: WISNA NOVERA, et al.
Published: (2021)